We really put investors Ahead of the Curve with our SVNT call. In early July, we wrote to our private members about Savient Pharmaceuticals and initiated a position. We scaled out of the position when our price target was met. In the process we realized a 240% profit by holding the stock just 9 weeks. As we were exiting, we published an article indicating that the investment thesis had changed, and recommending that investors should take profits. The stock has declined 20% since our sell recommendation.
Here is the screenshot showing our sell recommendation. (click to enlarge). Note, the buy recommendation was only made to our private members list, so you won't find it in the Google articles list. We save the best ideas for our members!
This article was published on SeekingAlpha.com on October 8, 2012
Savient Pharmaceuticals (SVNT) has experienced a dramatic recovery since early August. We believe that the investment thesis for SVNT has now changed. While SVNT was rallying this summer due to the contrarian trade against the Tang Capital lawsuit, the thesis going forward has to do with whether or not SVNT can sustain its revenue growth and expand its market into the European Union. Investors should act accordingly.
